AIM CLINICAL APPROPRIATENESS GUIDELINES FOR MUSCULOSKELETAL
The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines.
AIM Clinical Appropriateness Guidelines for Musculoskeletal are developed through a rigorous process integrating evidence-based literature with expert physician review. Guidelines for joint surgery, spine surgery, and interventional pain management are included below.
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR INTERVENTIONAL PAIN MANAGEMENT
The interventions addressed in the AIM Clinical Appropriateness Guidelines for Interventional Pain Management include epidural steroid injections; paravertebral facet injection, nerve block, and neurolysis; sacroiliac steroid injections; spinal cord stimulators; and regional sympathetic nerve block.
For Commercial members
OPEN THE GUIDELINES FOR INTERVENTIONAL PAIN MANAGEMENT EFFECTIVE JANUARY 01, 2020
COMING SOON INTERVENTIONAL PAIN MANAGEMENT GUIDELINES EFFECTIVE AUGUST 16, 2020
For Medicare members
OPEN THE GUIDELINES FOR INTERVENTIONAL PAIN MANAGEMENT EFFECTIVE JANUARY 01, 2020
COMING SOON INTERVENTIONAL PAIN MANAGEMENT GUIDELINES EFFECTIVE SEPTEMBER 26, 2020
For Medicaid members
OPEN THE GUIDELINES FOR INTERVENTIONAL PAIN MANAGEMENT EFFECTIVE JANUARY 01, 2020
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR JOINT SURGERY
The interventions addressed in the AIM Clinical Appropriateness Guidelines for Joint Surgery include total replacement of the hip, knee, and shoulder; arthroscopy of the hip, knee, and shoulder; treatment of osteochondral defects; and meniscal allograft transplantation.
For Commercial members
OPEN THE GUIDELINES FOR JOINT SURGERY EFFECTIVE MAY 17, 2020
For Medicare members
OPEN THE GUIDELINES FOR JOINT SURGERY EFFECTIVE JUNE 29, 2019
COMING SOON JOINT SURGERY GUIDELINES EFFECTIVE SEPTEMBER 26, 2020
For Medicaid members
OPEN THE GUIDELINES FOR JOINT SURGERY EFFECTIVE JUNE 29, 2019
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR SMALL JOINT SURGERY
The interventions addressed in the AIM Clinical Appropriateness Guidelines for Small Joint Surgery include hallux rigidus surgery; hallux valgus and bunionette surgery; and treatment of lesser toe deformities and ankle arthritis.
For Commercial members
COMING SOON SMALL JOINT SURGERY GUIDELINES EFFECTIVE NOVEMBER 1, 2020
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR SPINE SURGERY
The interventions addressed in the AIM Clinical Appropriateness Guidelines for Spine Surgery include bone grafts, bone growth stimulators, foraminotomies, fusions, laminectomy, discectomy, disc arthroplasty, treatment of spinal deformity, and vertebroplasty and kyphoplasty.
OPEN THE GUIDELINES FOR SPINE SURGERY
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR SACROILIAC JOINT FUSION
The intervention addressed in the AIM Clinical Appropriateness Guidelines for Sacroiliac Joint Fusion is the minimally invasive sacroiliac joint fusion with the IFuse system (titanium triangular implant).
OPEN THE GUIDELINES FOR SACROILIAC JOINT FUSION
AIM LEVEL OF CARE GUIDELINES FOR MUSCULOSKELETAL SURGERY AND PROCEDURES
The Level of Care Guidelines for Musculoskeletal Surgery and Procedures are intended to assist in determining the appropriate level of care necessary to safely and effectively perform the requested surgical procedure.
OPEN THE GUIDELINES FOR LEVEL OF CARE
COMING SOON LEVEL OF CARE GUIDELINES EFFECTIVE NOVEMBER 1, 2020
Trouble viewing the guidelines?
To open our guidelines, your computer needs Adobe Reader, a free and trusted software that allows you to view PDFs.
CLINICAL GUIDELINES ACCESS
Accessing Clinical Guidelines and Cancer Treatment Pathways
By clicking on the “I accept” button below, I acknowledge I accept the following terms and conditions when accessing and using the Clinical Guidelines and Cancer Treatment Pathways:
AIM Specialty Health® (AIM) has developed proprietary Clinical Guidelines and Cancer Treatment Pathways (together with any updates, referred to collectively as the “Guidelines and Pathways”). The Guidelines and Pathways are designed to evaluate and direct the appropriate utilization of certain health care services. They are based on data from peer-reviewed scientific literature, from criteria developed by specialty societies, and from guidelines adopted by other health care organizations. Access to these Guidelines and Pathways is being provided for informational purposes only. Although AIM has a process for updating its Guidelines and Pathways on a regular basis, due to the rapidly evolving nature of medicine, these Guidelines and Pathways may not reflect the most current evidence on a particular service or treatment.
The Guidelines and Pathways are protected by copyright of AIM as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Guidelines and Pathways and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Guidelines and Pathways unless authorized in writing by AIM.
The Guidelines and Pathways do not constitute medical advice and/or medical care and do not guarantee results or outcomes. The Guidelines and Pathways are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines or Pathways is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The Guidelines and Pathways do not address coverage, benefit, or other plan specific issues.
The Guidelines and Pathways are provided “as is” without warranty of any kind, either expressed or implied. AIM disclaims all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Guidelines.
About the AIM Clinical Appropriateness Guidelines for Genetic Testing
The AIM Clinical Appropriateness Guidelines for Genetic Testing (with any updates, referred to as the “Genetic Testing Guidelines”) were developed by and used with permission from Informed Medical Decisions, Inc.
The Genetic Testing Guidelines are protected by copyright of Informed Medical Decisions, Inc., as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Genetic Testing Guidelines and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Genetic Testing Guidelines unless authorized in writing by Informed Medical Decisions.
AIM and Informed Medical Decisions, Inc., disclaim all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Genetic Testing Guidelines.